191 related articles for article (PubMed ID: 36333070)
21. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Kundranda MN; Tibes R; Mesa RA
Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
[TBL] [Abstract][Full Text] [Related]
22. Accelerated and Blast Phase Myeloproliferative Neoplasms.
Jain T; Rampal RK
Hematol Oncol Clin North Am; 2021 Apr; 35(2):325-335. PubMed ID: 33641872
[TBL] [Abstract][Full Text] [Related]
23. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
[TBL] [Abstract][Full Text] [Related]
24. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Ferreira Cristina S; Polo B; Lacerda JF
Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
[TBL] [Abstract][Full Text] [Related]
25. Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
Mahdi D; Spiers J; Rampotas A; Polverelli N; McLornan DP
Br J Haematol; 2023 Oct; 203(2):169-181. PubMed ID: 37527977
[TBL] [Abstract][Full Text] [Related]
26. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
[TBL] [Abstract][Full Text] [Related]
27. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
28. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
29. Myeloproliferative Neoplasms with Monocytosis.
Morsia E; Gangat N
Curr Hematol Malig Rep; 2022 Feb; 17(1):46-51. PubMed ID: 34773576
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
[TBL] [Abstract][Full Text] [Related]
31. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
Patel AA; Odenike O
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
[TBL] [Abstract][Full Text] [Related]
32. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
33. Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.
Saha C; Attwell L; Harrison CN; McLornan DP
Blood Rev; 2022 Sep; 55():100947. PubMed ID: 35241294
[TBL] [Abstract][Full Text] [Related]
34. Outcomes and predictors of survival in blast phase myeloproliferative neoplasms.
Lancman G; Brunner A; Hoffman R; Mascarenhas J; Hobbs G
Leuk Res; 2018 Jul; 70():49-55. PubMed ID: 29807273
[TBL] [Abstract][Full Text] [Related]
35. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
[TBL] [Abstract][Full Text] [Related]
36. Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
Chauvet P; Nibourel O; Berthon C; Goursaud L; Carpentier B; Lionne-Huyghe P; Wemeau M; Quesnel B
Leuk Res; 2022 Jul; 118():106871. PubMed ID: 35633618
[TBL] [Abstract][Full Text] [Related]
37. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms.
Castillo Tokumori F; Al Ali N; Chan O; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e521-e525. PubMed ID: 35241387
[TBL] [Abstract][Full Text] [Related]
39. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.
Zhou S; Tremblay D; Hoffman R; Kremyanskaya M; Najfeld V; Li L; Moshier E; Mascarenhas J
Acta Haematol; 2021; 144(1):48-57. PubMed ID: 32160610
[TBL] [Abstract][Full Text] [Related]
40. Myeloproliferative Neoplasms: A Contemporary Review.
Tefferi A; Pardanani A
JAMA Oncol; 2015 Apr; 1(1):97-105. PubMed ID: 26182311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
